Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2023-06-15 Legal Proceedings Report
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
AKKADIAN PARTNERS OBTIENT LA NOMINATION D'UN EXPERT JUDICIAIRE - ET INVITE ERYTECH A REPORTER LE VOTE SUR LA FUSION AVEC PHERECYDES APRES LA REMISE DU RAPPORT DE L'EXPERT JUDICIAIRE
Legal Proceedings Report Classification · 1% confidence The document is a press release dated June 15, 2023, detailing a legal action taken by Akkadian Partners against Erytech regarding a proposed merger with Pherecydes. Specifically, it announces that a commercial court has appointed a judicial expert to review the merger parity and valuation methods, giving the expert four months to report. The text discusses the legal proceedings, the implications of the merger vote scheduled for June 23, 2023, and the potential consequences (annulment of the merger or director liability) if the parity is deemed unfair. This content directly relates to significant legal matters and regulatory actions involving the company, fitting the description of a Legal Proceedings Report (LTR). It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory announcement (RNS), but a specific update on litigation.
2023-06-15 French
ERYTECH annonce que le tribunal de commerce a débouté Akkadian de sa demande de report du vote sur la fusion avec Pherecydes Pharma
Legal Proceedings Report Classification · 1% confidence The document is a press release from ERYTECH Pharma announcing a legal development concerning a proposed merger with Pherecydes Pharma. Specifically, it states that the commercial court rejected Akkadian's request to postpone the shareholder vote on the merger. This announcement relates to a significant corporate action (merger) and a legal proceeding impacting that action. While it touches upon a shareholder vote, the core content is a legal/procedural update regarding a corporate transaction. It is not the actual merger agreement (TAR), the voting results (DVA), or a general legal proceeding report (LTR), but rather an announcement about the status of the merger process being cleared by a court. Given the options, this is best classified as a general corporate announcement related to a major transaction/legal hurdle. Since it is a specific announcement about a legal ruling impacting a corporate transaction (merger), and not a general legal proceeding report (LTR) or a general regulatory filing (RNS), the closest fit among the specific categories is difficult. However, since it directly relates to the mechanics and timeline of a major corporate transaction (merger), and is not a standard financial report, it falls under the category of significant corporate news. Given the options, and recognizing it's a press release about a legal ruling affecting a merger, it is most closely related to M&A Activity (TAR) or a general Regulatory Filing (RNS). Since it is a specific update on a legal challenge to a merger vote, and not the merger document itself, 'LTR' (Legal Proceedings Report) is plausible, but 'TAR' (M&A Activity) covers the context of the underlying transaction. Given the focus on the court ruling rejecting the postponement of the merger vote, it is a specific legal update impacting a transaction. I will classify it as LTR as it is a report on a legal proceeding outcome, even though the context is M&A.
2023-06-14 French
ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma
Legal Proceedings Report Classification · 1% confidence The document is a press release titled "ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma." It discusses a legal ruling related to a proposed merger and shareholder voting, and it references a future vote date (June 23, 2023). This content relates to corporate actions, legal proceedings, and shareholder matters. Since it is an announcement regarding a legal/corporate event (rejection of a postponement request for a merger vote) rather than a full financial report (10-K, IR) or a specific insider trade (DIRS), the most fitting categories are Legal Proceedings Report (LTR) or Regulatory Filings (RNS). Given the focus on a court decision impacting a corporate transaction (merger vote), LTR is highly relevant. However, the core event is an announcement about a corporate action/legal development, which often falls under general regulatory announcements if a more specific category like TAR (M&A Activity) isn't a perfect fit (as this is about the *process* of the merger vote, not the merger itself). Since it explicitly details a legal proceeding outcome ('Lyon Commercial Court has rejected Akkadian's request'), LTR is the strongest fit among the specific options. It is not a standard Earnings Release (ER), Interim Report (IR), or a proxy statement (PSI).
2023-06-14 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 mai 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2023" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of May 31, 2023). It explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers, the French financial market regulator). The content is a table showing the evolution of the total number of shares and voting rights month-over-month. This type of mandatory periodic disclosure regarding the capital structure and voting rights is typically classified as a regulatory filing or a specific capital/share update. Given the options, it most closely aligns with a notification about share capital changes or a general regulatory filing. Since it details the total number of shares and voting rights, it is a specific disclosure related to the share structure. The closest fit among the provided codes is 'SHA' (Share Issue/Capital Change) or 'RNS' (Regulatory Filings). Because it is a mandatory monthly disclosure of the total share count and voting rights, which directly impacts capital structure, 'SHA' is a strong candidate, but 'RNS' is often used for mandatory regulatory updates that aren't strictly an 'issue' or 'repurchase'. However, the core data is about the total shares and voting rights, which is a fundamental aspect of capital structure reporting. Let's re-evaluate the definitions. 'SHA' is for 'Announcement regarding new share issues, stock splits, or other capital changes.' This document reports the *current state* of the capital structure, not necessarily a *change event* itself, although changes are visible in the table (e.g., the jump on May 15th). 'RNS' is the general regulatory fallback. Given the specific nature of reporting total voting rights under AMF rules, this is a highly specific regulatory disclosure. In many contexts, mandatory capital structure updates fall under general regulatory reporting. Since it is a monthly report on the total number of shares and voting rights, it is a specific regulatory filing. If we must choose between the specific capital change code (SHA) and the general regulatory code (RNS), the content is a routine, mandated update on the capital base, which fits well under 'RNS' as a general regulatory filing, or potentially 'SHA' if the focus is on the capital base itself. Given the context of mandatory French regulatory reporting, 'RNS' (Regulatory Filings) is the most appropriate general bucket for routine, mandated disclosures that don't fit perfectly into ER, 10-K, or DIV. However, since the data *is* about the share count, 'SHA' is also plausible. Let's check if there is a better fit. It is not an earnings release (ER), not an annual report (10-K), not a dividend notice (DIV). It is a mandatory regulatory filing detailing the share count. I will classify it as RNS as it is a routine regulatory disclosure mandated by the AMF, which serves as the best general regulatory category when a more specific one isn't perfect. Upon further review, mandatory disclosures of total shares and voting rights are often categorized under capital structure updates. Since the document shows the total share count and voting rights, which is a direct reflection of the capital structure, 'SHA' (Share Issue/Capital Change) is a reasonable fit, even if it's a reporting of the current state rather than an announcement of a new transaction. Given the options, and the focus on the total number of shares, SHA is slightly more specific than RNS. I will lean towards RNS as the most accurate fallback for routine regulatory reporting not explicitly about a transaction or a full financial report.
2023-06-13 French
Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital - May 31, 2023." It explicitly references Article 223-16 of the French Autorité des Marchés Financiers (AMF) general regulation and provides a table detailing the evolution of the total number of shares and voting rights over several months, culminating in the May 31, 2023, figure. This type of regular disclosure concerning the total number of shares and voting rights is a specific regulatory requirement, often related to transparency regarding capital structure changes or compliance with ownership thresholds. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most fitting category, as the core content is the official count of voting rights. While it's a monthly update rather than a final result of a specific vote, the focus on voting rights makes DVA superior to the general 'RNS' fallback.
2023-06-13 English
AKKADIAN PARTNERS REJECTS THE LIQUIDATION OF ERYTECH IN THE EVENT THAT THE MERGER WITH PHERECYDES FAILS
Board/Management Information Classification · 1% confidence The document is a press release dated June 13, 2023, from Akkadian Partners reacting to a previous press release by ERYTECH Pharma regarding a proposed merger with PHERECYDES. Akkadian Partners is explicitly rejecting the merger terms and proposing an alternative slate of 5 new directors if the merger fails, threatening that the current management intends to liquidate the company otherwise. This content deals with corporate governance, management/board changes, and shareholder activism related to a potential transaction (merger). It is not a formal regulatory filing like a 10-K, an earnings release, or a dividend notice. The proposal of new directors and the critique of the current board structure strongly align with 'Board/Management Information' (MANG) or potentially 'Governance Information' (CGR). Since the core action is proposing a new board slate in response to a strategic decision (merger failure leading to liquidation threat), MANG is the most fitting category for announcing changes/alternatives for the board/management team.
2023-06-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.